Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients

Y. Xu, D. C. Gaudette, J. D. Boynton, A. Frankel, X. J. Fang, A. Sharma, J. Hurteau, G. Casey, A. Goodbody, A. Mellors, B. J. Holub, G. B. Mills

Research output: Contribution to journalArticle

285 Citations (Scopus)

Abstract

Ascites from ovarian cancer patients contain potent growth-promoting activity toward human ovarian cancer cells both in vitro and in vivo. This activity is associated with rapid increases in cytosolic free calcium ([Ca2+](i)) as a consequence of phosphoinositide hydrolysis. In this study, we describe the purification, characterization, and identification of an ovarian cancer activating factor (OCAF) from ascites of ovarian cancer patients. We have isolated OCAF by a combination of solvent extraction, silica gel chromatography, and TLC. Mass spectral analysis, phospholipase sensitivity, and gas chromatographic behavior of purified OCAF indicate that OCAF is composed of various species of lysophosphatidic acid (LPA), including LPAs with polyunsaturated fatty acyl chains (linoleic, arachidonic, and docosahexaenoic acids). However, OCAF is more potent than sn-1 palmitoyl, oleoyl, or stearoyl LPA in increasing [Ca2+](i) in ovarian cancer cells. The ability of OCAF to alter [Ca2+](i) is sensitive to the effects of lipoxidase, whereas the activity of sn-1 oleoyl, stearoyl, or palmitoyl LPA is not, suggesting that polyunsaturated bonds in the fatty acyl chain of OCAF may account for its increased ability to activate ovarian cancer cells. Furthermore, a sn-2 linoleoyl LPA generated by phospholipase A1 treatment of synthetic phosphatidic acid is much more active than are sn-1 palmitoyl, stearoyl, or oleoyl LPA in increasing [Ca2+](i) in ovarian cancer cells. Taken together, these data suggest that the ability of OCAF to increase cellular calcium may reside in the structure and/or location of the fatty acyl chain of LPA. Purified OCAF, at concentrations similar to those present in ascites from ovarian cancer patients, was sufficient to induce proliferation of ovarian cancer cells, as indicated by thymidine incorporation, reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, or colony formation. However, even at optimal concentrations of OCAF, proliferation was lower than that induced by FCS or ascites from ovarian cancer patients, indicating that, although OCAF may be a major regulator of ovarian cancer cells in vivo, it is not the sole mediator present in ascites, and it likely functions in concert with other growth factor activities.

Original languageEnglish (US)
Pages (from-to)1223-1232
Number of pages10
JournalClinical Cancer Research
Volume1
Issue number10
StatePublished - 1995

Fingerprint

Ascites
Ovarian Neoplasms
Phospholipases A1
Arachidonic Acids
Calcium
Phosphatidic Acids
Lipoxygenase
Phospholipases
Silica Gel

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Xu, Y., Gaudette, D. C., Boynton, J. D., Frankel, A., Fang, X. J., Sharma, A., ... Mills, G. B. (1995). Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clinical Cancer Research, 1(10), 1223-1232.

Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. / Xu, Y.; Gaudette, D. C.; Boynton, J. D.; Frankel, A.; Fang, X. J.; Sharma, A.; Hurteau, J.; Casey, G.; Goodbody, A.; Mellors, A.; Holub, B. J.; Mills, G. B.

In: Clinical Cancer Research, Vol. 1, No. 10, 1995, p. 1223-1232.

Research output: Contribution to journalArticle

Xu, Y, Gaudette, DC, Boynton, JD, Frankel, A, Fang, XJ, Sharma, A, Hurteau, J, Casey, G, Goodbody, A, Mellors, A, Holub, BJ & Mills, GB 1995, 'Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients', Clinical Cancer Research, vol. 1, no. 10, pp. 1223-1232.
Xu, Y. ; Gaudette, D. C. ; Boynton, J. D. ; Frankel, A. ; Fang, X. J. ; Sharma, A. ; Hurteau, J. ; Casey, G. ; Goodbody, A. ; Mellors, A. ; Holub, B. J. ; Mills, G. B. / Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. In: Clinical Cancer Research. 1995 ; Vol. 1, No. 10. pp. 1223-1232.
@article{52a6270c9aa74219a5cd6aa2c71e898c,
title = "Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients",
abstract = "Ascites from ovarian cancer patients contain potent growth-promoting activity toward human ovarian cancer cells both in vitro and in vivo. This activity is associated with rapid increases in cytosolic free calcium ([Ca2+](i)) as a consequence of phosphoinositide hydrolysis. In this study, we describe the purification, characterization, and identification of an ovarian cancer activating factor (OCAF) from ascites of ovarian cancer patients. We have isolated OCAF by a combination of solvent extraction, silica gel chromatography, and TLC. Mass spectral analysis, phospholipase sensitivity, and gas chromatographic behavior of purified OCAF indicate that OCAF is composed of various species of lysophosphatidic acid (LPA), including LPAs with polyunsaturated fatty acyl chains (linoleic, arachidonic, and docosahexaenoic acids). However, OCAF is more potent than sn-1 palmitoyl, oleoyl, or stearoyl LPA in increasing [Ca2+](i) in ovarian cancer cells. The ability of OCAF to alter [Ca2+](i) is sensitive to the effects of lipoxidase, whereas the activity of sn-1 oleoyl, stearoyl, or palmitoyl LPA is not, suggesting that polyunsaturated bonds in the fatty acyl chain of OCAF may account for its increased ability to activate ovarian cancer cells. Furthermore, a sn-2 linoleoyl LPA generated by phospholipase A1 treatment of synthetic phosphatidic acid is much more active than are sn-1 palmitoyl, stearoyl, or oleoyl LPA in increasing [Ca2+](i) in ovarian cancer cells. Taken together, these data suggest that the ability of OCAF to increase cellular calcium may reside in the structure and/or location of the fatty acyl chain of LPA. Purified OCAF, at concentrations similar to those present in ascites from ovarian cancer patients, was sufficient to induce proliferation of ovarian cancer cells, as indicated by thymidine incorporation, reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, or colony formation. However, even at optimal concentrations of OCAF, proliferation was lower than that induced by FCS or ascites from ovarian cancer patients, indicating that, although OCAF may be a major regulator of ovarian cancer cells in vivo, it is not the sole mediator present in ascites, and it likely functions in concert with other growth factor activities.",
author = "Y. Xu and Gaudette, {D. C.} and Boynton, {J. D.} and A. Frankel and Fang, {X. J.} and A. Sharma and J. Hurteau and G. Casey and A. Goodbody and A. Mellors and Holub, {B. J.} and Mills, {G. B.}",
year = "1995",
language = "English (US)",
volume = "1",
pages = "1223--1232",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients

AU - Xu, Y.

AU - Gaudette, D. C.

AU - Boynton, J. D.

AU - Frankel, A.

AU - Fang, X. J.

AU - Sharma, A.

AU - Hurteau, J.

AU - Casey, G.

AU - Goodbody, A.

AU - Mellors, A.

AU - Holub, B. J.

AU - Mills, G. B.

PY - 1995

Y1 - 1995

N2 - Ascites from ovarian cancer patients contain potent growth-promoting activity toward human ovarian cancer cells both in vitro and in vivo. This activity is associated with rapid increases in cytosolic free calcium ([Ca2+](i)) as a consequence of phosphoinositide hydrolysis. In this study, we describe the purification, characterization, and identification of an ovarian cancer activating factor (OCAF) from ascites of ovarian cancer patients. We have isolated OCAF by a combination of solvent extraction, silica gel chromatography, and TLC. Mass spectral analysis, phospholipase sensitivity, and gas chromatographic behavior of purified OCAF indicate that OCAF is composed of various species of lysophosphatidic acid (LPA), including LPAs with polyunsaturated fatty acyl chains (linoleic, arachidonic, and docosahexaenoic acids). However, OCAF is more potent than sn-1 palmitoyl, oleoyl, or stearoyl LPA in increasing [Ca2+](i) in ovarian cancer cells. The ability of OCAF to alter [Ca2+](i) is sensitive to the effects of lipoxidase, whereas the activity of sn-1 oleoyl, stearoyl, or palmitoyl LPA is not, suggesting that polyunsaturated bonds in the fatty acyl chain of OCAF may account for its increased ability to activate ovarian cancer cells. Furthermore, a sn-2 linoleoyl LPA generated by phospholipase A1 treatment of synthetic phosphatidic acid is much more active than are sn-1 palmitoyl, stearoyl, or oleoyl LPA in increasing [Ca2+](i) in ovarian cancer cells. Taken together, these data suggest that the ability of OCAF to increase cellular calcium may reside in the structure and/or location of the fatty acyl chain of LPA. Purified OCAF, at concentrations similar to those present in ascites from ovarian cancer patients, was sufficient to induce proliferation of ovarian cancer cells, as indicated by thymidine incorporation, reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, or colony formation. However, even at optimal concentrations of OCAF, proliferation was lower than that induced by FCS or ascites from ovarian cancer patients, indicating that, although OCAF may be a major regulator of ovarian cancer cells in vivo, it is not the sole mediator present in ascites, and it likely functions in concert with other growth factor activities.

AB - Ascites from ovarian cancer patients contain potent growth-promoting activity toward human ovarian cancer cells both in vitro and in vivo. This activity is associated with rapid increases in cytosolic free calcium ([Ca2+](i)) as a consequence of phosphoinositide hydrolysis. In this study, we describe the purification, characterization, and identification of an ovarian cancer activating factor (OCAF) from ascites of ovarian cancer patients. We have isolated OCAF by a combination of solvent extraction, silica gel chromatography, and TLC. Mass spectral analysis, phospholipase sensitivity, and gas chromatographic behavior of purified OCAF indicate that OCAF is composed of various species of lysophosphatidic acid (LPA), including LPAs with polyunsaturated fatty acyl chains (linoleic, arachidonic, and docosahexaenoic acids). However, OCAF is more potent than sn-1 palmitoyl, oleoyl, or stearoyl LPA in increasing [Ca2+](i) in ovarian cancer cells. The ability of OCAF to alter [Ca2+](i) is sensitive to the effects of lipoxidase, whereas the activity of sn-1 oleoyl, stearoyl, or palmitoyl LPA is not, suggesting that polyunsaturated bonds in the fatty acyl chain of OCAF may account for its increased ability to activate ovarian cancer cells. Furthermore, a sn-2 linoleoyl LPA generated by phospholipase A1 treatment of synthetic phosphatidic acid is much more active than are sn-1 palmitoyl, stearoyl, or oleoyl LPA in increasing [Ca2+](i) in ovarian cancer cells. Taken together, these data suggest that the ability of OCAF to increase cellular calcium may reside in the structure and/or location of the fatty acyl chain of LPA. Purified OCAF, at concentrations similar to those present in ascites from ovarian cancer patients, was sufficient to induce proliferation of ovarian cancer cells, as indicated by thymidine incorporation, reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, or colony formation. However, even at optimal concentrations of OCAF, proliferation was lower than that induced by FCS or ascites from ovarian cancer patients, indicating that, although OCAF may be a major regulator of ovarian cancer cells in vivo, it is not the sole mediator present in ascites, and it likely functions in concert with other growth factor activities.

UR - http://www.scopus.com/inward/record.url?scp=0028871499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028871499&partnerID=8YFLogxK

M3 - Article

C2 - 9815916

AN - SCOPUS:0028871499

VL - 1

SP - 1223

EP - 1232

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -